SIFI reports positive results from 044/si phase 3 clinical trial further highlighting strength of its NETILDEX® franchise

SIFI, an Italian leader in ophthalmology, is pleased to announce the successful conclusion of a Phase 3 clinical trial aimed at demonstrating the non-inferiority of NETILDEX® gel administered twice daily (BID) vs. NETILDEX® solution administered four times daily (QID) in the control of inflammation after cataract surgery.